An exploration of methods to enable equitable access to non-invasive prenatal screening - Ehrich, Mathias; Sagaser, Katelynn G.; Ellison, Christopher K.; Wu, Allison Chia-Yi; Hutchison, Don C.; Porreco, Richard P.; Bellesheim, Deborah; Patil, Avinash S.; Shulman, Lee P.; van den Boom, Dirk (medRxiv, 2022)
Objective To explore capillary blood collection as a potential method to enable more equitable access to non-invasive prenatal screening (NIPS) for aneuploidy.Methods All participants contributed venous and capillary blood samples in this comparative study. Samples were analyzed using standard NIPS methods. Venous samples were used as the basis. Multiple parameters were compared including specimen collection, cfDNA characteristics, and NIPS outcome.Results Venous and capillary sample pairs were successfully collected for comparative analysis from 202 participants. Cell free DNA (cfDNA) size profiles from venous vs capillary blood were not different (p >0.05). Evaluation of fetoplacental cfDNA contribution in plasma revealed no statistically significant difference in venous vs capillary samples. Elevated Z-scores for trisomy 21 (n=13), trisomy 18 (n=2), or trisomy 13 (n=1) were concordant between venous and capillary samples in all 16 pairs.Conclusion We have demonstrated that sufficient capillary blood volumes can be obtained for NIPS. Furthermore, capillary and venous cfDNA samples have comparable characteristics. As NIPS results from capillary blood collections are equivalent to NIPS results obtained from venous blood, capillary blood collections are a potential candidate for a distributable NIPS system which promotes equitable access to NIPS for all pregnant patients.Competing Interest StatementAuthors ME, KGS, CKE, ACYW, DCH, and DvdB are employees and shareholders of Juno Diagnostics. Author DB receives an honorarium for service on Juno Diagnostics clinical advisory board. Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Aspire Independent Review Board gave approval for this work (#Juno-2017-0001).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors